Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer
April 2, 2020 10:30 amBy Gina Columbus
Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival (RFS) compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease, according to phase II results from the … Read more